title: Serum-protein interactions with anticancer Ru(III) complexes KP1019 and KP418 characterized by EPR.
abstract: The compounds imidazolium [trans-[RuCl(4)(1H-imidazole)(2)] (KP418) and indazolium [trans-RuCl(4)(1H-indazole)(2)] (KP1019) both show significant anticancer activity, with the latter recently having completed phase I clinical trials. An important component of this success has been associated with targeted delivery of the complexes to cancer cells by serum proteins. In this study, electron paramagnetic resonance (EPR) measurements, combined with incubation under physiological conditions, and separation of protein-bound fractions, have been used to characterize the interactions of these complexes with human serum albumin (hsA), human serum transferrin (hsTf) apoprotein, and whole human serum. The strong EPR signals observed in these experiments demonstrate that both complexes are primarily retained in the 3+ oxidation state in the presence of serum components. Rapid, noncovalent binding of KP1019 was observed in the presence of both hsA and serum, indicating that the predominant interactions occur within the hydrophobic binding sites of hsA. This sequestering process correlates with the low levels of side effects observed in clinical trials of the complex. At longer incubation times, the noncovalently bound complexes are converted slowly to a protein-coordinated form. Noncovalent interactions are not observed in the presence apo-hsTf, where only slow binding of KP1019 via ligand exchange with the protein occurs. By contrast, hydrophobic interactions of KP418 with hsA only occur with the aquated products of the complex, a process that also dominates in serum. In the presence of apo-hsTf, KP418 interacts directly with the protein through exchange of ligands, as observed with KP1019.
authors.affiliation: Department of Chemistry, Simon Fraser University, Burnaby, BC, Canada.
authors.forename: Naniye
authors.initials: N
authors.lastname: Cetinbas
authors.forename: Michael I
authors.initials: MI
authors.lastname: Webb
authors.forename: Joshua A
authors.initials: JA
authors.lastname: Dubland
authors.forename: Charles J
authors.initials: CJ
authors.lastname: Walsby
mesh_terms: D000970:Antineoplastic Agents / Q000737:chemistry*; D001059:Apoproteins / Q000737:chemistry*; D001665:Binding Sites; D004578:Electron Spin Resonance Spectroscopy; D006801:Humans; D007191:Indazoles / Q000737:chemistry*; D008024:Ligands; D015394:Molecular Structure; D009942:Organometallic Compounds / Q000737:chemistry*; D017975:Ruthenium Compounds / Q000737:chemistry*; D012709:Serum Albumin / Q000737:chemistry*; D013329:Structure-Activity Relationship
chemical_list: D000970:Antineoplastic Agents; D001059:Apoproteins; D007191:Indazoles; D008024:Ligands; D009942:Organometallic Compounds; D017975:Ruthenium Compounds; D012709:Serum Albumin; C521720:imidazolium tetrachlorobis(1H-imidazole)ruthenate(III); C499292:indazolium trans-(tetrachlorobis(1H-indazole)ruthenate (III))
references.citation: Biochim Biophys Acta. 1997 Mar 14;1331(1):1-40
references.pmid: 9325434
references.citation: J Biol Chem. 1994 Jan 28;269(4):2581-8
references.pmid: 8300587
references.citation: Anal Biochem. 2005 Jun 15;341(2):326-33
references.pmid: 15907879
references.citation: Semin Oncol. 1992 Apr;19(2 Suppl 3):73-81
references.pmid: 1373006
references.citation: Arzneimittelforschung. 1992 Jun;42(6):821-4
references.pmid: 1418038
references.citation: J Inorg Biochem. 2000 Mar;78(4):341-6
references.pmid: 10857915
references.citation: Cancer Chemother Pharmacol. 2004 Jul;54(1):71-8
references.pmid: 15034754
references.citation: J Inorg Biochem. 2004 May;98(5):903-16
references.pmid: 15134936
references.citation: Br J Cancer. 2002 May 20;86(10):1652-7
references.pmid: 12085218
references.citation: Mol Pharmacol. 1975 Nov;11(6):824-32
references.pmid: 1207674
references.citation: J Inorg Biochem. 2008 May-Jun;102(5-6):1060-5
references.pmid: 18222004
references.citation: Eur J Cancer. 1997 Dec;33(14):2404-10
references.pmid: 9616290
references.citation: Met Based Drugs. 1996;3(1):15-23
references.pmid: 18472789
references.citation: J Inorg Biochem. 2004 Feb;98(2):402-12
references.pmid: 14729322
references.citation: Anticancer Drugs. 2009 Feb;20(2):97-103
references.pmid: 19209025
references.citation: J Biol Inorg Chem. 2008 Aug;13(6):909-18
references.pmid: 18438690
references.citation: Dalton Trans. 2004 Aug 7;(15):2347-51
references.pmid: 15278129
references.citation: Eur J Cancer. 2002 Feb;38(3):427-35
references.pmid: 11818210
references.citation: J Biol Inorg Chem. 2001 Apr;6(4):435-45
references.pmid: 11372202
references.citation: Met Based Drugs. 1996;3(5):243-60
references.pmid: 18472901
references.citation: Hepatology. 2005 Jun;41(6):1211-9
references.pmid: 15915465
references.citation: Biochem Pharmacol. 1987 Aug 15;36(16):2661-6
references.pmid: 3111487
references.citation: Invest New Drugs. 2003 Nov;21(4):401-11
references.pmid: 14586207
references.citation: J Chromatogr B Biomed Sci Appl. 2001 Aug 5;759(1):81-9
references.pmid: 11499632
references.citation: J Appl Toxicol. 1998 Mar-Apr;18(2):93-101
references.pmid: 9570691
references.citation: J Cancer Res Clin Oncol. 2005 Feb;131(2):101-10
references.pmid: 15503135
references.citation: Inorg Chem. 2005 Jan 10;44(1):122-32
references.pmid: 15627368
references.citation: Biochem Pharmacol. 1993 Jun 22;45(12):2411-6
references.pmid: 8328979
references.citation: Inorg Chem. 2005 Jul 11;44(14):4897-9
references.pmid: 15998012
references.citation: Chem Rev. 2006 Jun;106(6):2224-48
references.pmid: 16771448
references.citation: Inorg Chem. 2004 Nov 1;43(22):7083-93
references.pmid: 15500346
references.citation: Met Based Drugs. 1994;1(2-3):169-73
references.pmid: 18476228
references.citation: Biochim Biophys Acta. 1973 Oct 18;322(2):195-203
references.pmid: 4358082
references.citation: J Inorg Biochem. 2006 May;100(5-6):891-904
references.pmid: 16603249
references.citation: Dalton Trans. 2006 Apr 28;(16):1929-33
references.pmid: 16609762
references.citation: Curr Top Med Chem. 2004;4(15):1525-35
references.pmid: 15579094
references.citation: J Biol Inorg Chem. 2001 Mar;6(3):292-9
references.pmid: 11315565
references.citation: Mol Pharmacol. 1976 Nov;12(6):1052-61
references.pmid: 1004490
references.citation: J Inorg Biochem. 2004 Jun;98(6):1135-42
references.pmid: 15149825
references.citation: BMC Struct Biol. 2003 Jul 7;3:6
references.pmid: 12846933
references.citation: Chem Rev. 1999 Sep 8;99(9):2511-34
references.pmid: 11749489
references.citation: J Med Chem. 2005 Apr 21;48(8):2831-7
references.pmid: 15828821
references.citation: Biochemistry. 2005 Jun 7;44(22):8013-21
references.pmid: 15924420
references.citation: J Med Chem. 2007 May 3;50(9):2185-93
references.pmid: 17402720
references.citation: J Inorg Biochem. 1999 Mar;73(3):123-8
references.pmid: 10331241
references.citation: Electrophoresis. 2008 May;29(10):2224-32
references.pmid: 18512673
references.citation: Curr Pharm Des. 2003;9(25):2078-89
references.pmid: 14529417
references.citation: Dalton Trans. 2006 Apr 14;(14):1796-802
references.pmid: 16568190
references.citation: Curr Med Chem. 2006;13(9):1085-107
references.pmid: 16611086
references.citation: Met Based Drugs. 2000;7(4):225-32
references.pmid: 18475949
references.citation: Blood. 1979 Jun;53(6):1058-65
references.pmid: 444649
references.citation: Inorg Chem. 2008 Jul 21;47(14):6513-23
references.pmid: 18553904
references.citation: Inorg Chem. 1996 Aug 14;35(17):4896-4903
references.pmid: 11666690
references.citation: Adv Protein Chem. 1985;37:161-245
references.pmid: 3904348
references.citation: J Inorg Biochem. 2008 Feb;102(2):347-58
references.pmid: 18022241
references.citation: Cancer Lett. 2005 Aug 26;226(2):115-21
references.pmid: 16039951